Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

657 sites for NCT02912559

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Colon Adenocarcinoma, +1 more condition

atezolizumab, +3 more drugs

chemotherapy, +1 more type

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

146 sites for NCT04008030

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Carcinoma

ipilimumab, +1 more drug

immunotherapy

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

332 sites for NCT02997228

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Adenocarcinoma

atezolizumab, +4 more drugs

chemotherapy, +2 more types

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

191 sites for NCT04214067

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Endometrial Endometrioid Adenocarcinoma

brachytherapy, +2 more drugs

immunotherapy, +1 more type

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer

116 sites for NCT04751370

Deficient DNA Mismatch Repair (dMMR), +1 more biomarker

Rectal Adenocarcinoma

ipilimumab, +3 more drugs

immunotherapy, +2 more types

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

259 sites for NCT03609216

ARID1A Loss, +122 more biomarkers

Bladder Urothelial Carcinoma

chemoradiotherapy, +6 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

25 sites for NCT02628067

Deficient DNA Mismatch Repair (dMMR), +6 more biomarkers

Anal Squamous Cell Carcinoma, +18 more conditions

pembrolizumab

immunotherapy

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

83 sites for NCT02715284

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Endometrial Carcinoma, +11 more conditions

dostarlimab

immunotherapy

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

48 sites for NCT04632992

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types

Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

31 sites for NCT04895722

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Adenocarcinoma

MK-1308A, +4 more drugs

immunotherapy

Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

1 site for NCT04157985

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +16 more conditions

anti-PD-1 antibody, +1 more drug

immunotherapy